BTIG Research Reaffirms Buy Rating for Caris Life Sciences (NASDAQ:CAI)

Caris Life Sciences (NASDAQ:CAI)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a note issued to investors on Thursday, Benzinga reports. They presently have a $38.00 price target on the stock. BTIG Research‘s price objective would indicate a potential upside of 14.39% from the stock’s current price.

CAI has been the subject of several other research reports. UBS Group set a $38.00 price target on Caris Life Sciences in a research note on Thursday. TD Cowen reissued a “buy” rating on shares of Caris Life Sciences in a research note on Thursday. Wall Street Zen upgraded shares of Caris Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, August 16th. Canaccord Genuity Group raised their target price on shares of Caris Life Sciences from $22.00 to $30.00 and gave the stock a “hold” rating in a research note on Monday, October 19th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.91.

Caris Life Sciences Price Performance

Shares of CAI opened at $33.22 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53. Caris Life Sciences has a fifty-two week low of $14.19 and a fifty-two week high of $36.50. The firm has a 50-day simple moving average of $29.52 and a 200-day simple moving average of $21.74. The company has a market capitalization of $9.39 billion, a price-to-earnings ratio of 91.25 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.02. The firm had revenue of $275.36 million for the quarter. Caris Life Sciences had a return on equity of 18.77% and a net margin of 10.62%. The business’s revenue was up 27.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS. On average, equities research analysts anticipate that Caris Life Sciences will post 0.13 earnings per share for the current year.

Insider Activity at Caris Life Sciences

In related news, insider Brian Brille sold 400,000 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $30.33, for a total transaction of $12,132,000.00. Following the transaction, the insider owned 230,303 shares of the company’s stock, valued at $6,985,089.99. This represents a 63.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider John Russel Denton sold 7,500 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total value of $238,650.00. Following the completion of the transaction, the insider owned 174,855 shares of the company’s stock, valued at $5,563,886.10. The trade was a 4.11% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,004,712 shares of company stock worth $27,205,419 over the last three months. 50.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Caris Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its stake in shares of Caris Life Sciences by 839.4% during the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after acquiring an additional 1,469 shares during the last quarter. Fifth Third Bancorp acquired a new position in Caris Life Sciences in the 1st quarter valued at about $31,000. Sterling Capital Management LLC raised its stake in Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock valued at $34,000 after purchasing an additional 1,083 shares during the last quarter. MCF Advisors LLC purchased a new position in Caris Life Sciences in the 2nd quarter valued at about $36,000. Finally, Trifecta Capital Advisors LLC purchased a new position in Caris Life Sciences in the 2nd quarter valued at about $37,000.

Key Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris raised its 2026 revenue guidance to $1.04 billion–$1.05 billion, implying 28%–29% annual growth. The company attributed its results to demand for molecular profiling services, including about 61,500 clinical cases and more than 358,000 oncology tests. Caris Q3 results and increased guidance
• Positive Sentiment: Third-quarter revenue rose 27% year over year to $275.4 million, while earnings of $0.05 per share beat analysts’ $0.03 estimate. The revenue growth and earnings beat are supportive signals for investors. Caris Q3 earnings and revenue beat estimates
• Neutral Sentiment: A valuation analysis framed CAI as potentially 14% below fair value following the raised outlook. That estimate is model-dependent and does not guarantee further share gains. Caris valuation analysis
• Negative Sentiment: Profitability was weaker year over year: net income fell 37% amid higher expenses, and EPS declined from $0.08 in the year-ago quarter to $0.05. This tempers the positive revenue and guidance news. Caris Q3 net income and outlook

Caris Life Sciences Company Profile

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.